Cargando…
Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection
Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745470/ https://www.ncbi.nlm.nih.gov/pubmed/35011936 http://dx.doi.org/10.3390/jcm11010193 |
_version_ | 1784630353051254784 |
---|---|
author | Kim, Ji Eun Kim, Tae Jun Lee, Hyuk Lee, Yeong Chan Chung, Hwe Hoon Min, Yang Won Min, Byung-Hoon Lee, Jun Haeng Kim, Jae J. |
author_facet | Kim, Ji Eun Kim, Tae Jun Lee, Hyuk Lee, Yeong Chan Chung, Hwe Hoon Min, Yang Won Min, Byung-Hoon Lee, Jun Haeng Kim, Jae J. |
author_sort | Kim, Ji Eun |
collection | PubMed |
description | Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important. The anti-tumor activity of aspirin has been demonstrated, but its efficacy in preventing MGC remains controversial. We evaluated the effect of aspirin on metachronous recurrence in H. pylori-negative patients. Methods: A total of 4351 patients were evaluated between January 2007 and December 2016, and 2151 patients who met the inclusion criteria were analyzed. The primary outcome was the cumulative incidence of MGC after an endoscopic resection for EGC. Results: During a 5-year median follow-up (interquartile range, 3.5–6.2), MGC developed in 176 (7.7%) patients, with a cumulative incidence of 89.4% in aspirin users and 92.7% in non-users; this difference was not statistically significant (p = 0.64). The duration of aspirin uses and the occurrence of MGC in both groups were not significantly different. There was no significant difference between groups when the duration of aspirin use was categorized into ≤1 year (hazard ratio (HR), 0.64; 0.20–2.01, p = 0.45), 1–4 years (HR, 1.35; 0.66–2.76, p = 0.41), and >4 years (HR, 1.17; 0.67–2.03, p = 0.58). Conclusions: Aspirin use was not associated with a lower risk of MGC in H. pylori-negative patients. Further prospective studies are needed. |
format | Online Article Text |
id | pubmed-8745470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87454702022-01-11 Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection Kim, Ji Eun Kim, Tae Jun Lee, Hyuk Lee, Yeong Chan Chung, Hwe Hoon Min, Yang Won Min, Byung-Hoon Lee, Jun Haeng Kim, Jae J. J Clin Med Article Introduction: Helicobacter pylori (H. pylori) eradication can prevent metachronous gastric cancer (MGC) after the performance of an endoscopic resection for early gastric cancer (EGC). However, 50% of infections persist after eradication, and the identification of MGC protective factors is important. The anti-tumor activity of aspirin has been demonstrated, but its efficacy in preventing MGC remains controversial. We evaluated the effect of aspirin on metachronous recurrence in H. pylori-negative patients. Methods: A total of 4351 patients were evaluated between January 2007 and December 2016, and 2151 patients who met the inclusion criteria were analyzed. The primary outcome was the cumulative incidence of MGC after an endoscopic resection for EGC. Results: During a 5-year median follow-up (interquartile range, 3.5–6.2), MGC developed in 176 (7.7%) patients, with a cumulative incidence of 89.4% in aspirin users and 92.7% in non-users; this difference was not statistically significant (p = 0.64). The duration of aspirin uses and the occurrence of MGC in both groups were not significantly different. There was no significant difference between groups when the duration of aspirin use was categorized into ≤1 year (hazard ratio (HR), 0.64; 0.20–2.01, p = 0.45), 1–4 years (HR, 1.35; 0.66–2.76, p = 0.41), and >4 years (HR, 1.17; 0.67–2.03, p = 0.58). Conclusions: Aspirin use was not associated with a lower risk of MGC in H. pylori-negative patients. Further prospective studies are needed. MDPI 2021-12-30 /pmc/articles/PMC8745470/ /pubmed/35011936 http://dx.doi.org/10.3390/jcm11010193 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Ji Eun Kim, Tae Jun Lee, Hyuk Lee, Yeong Chan Chung, Hwe Hoon Min, Yang Won Min, Byung-Hoon Lee, Jun Haeng Kim, Jae J. Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title | Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title_full | Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title_fullStr | Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title_full_unstemmed | Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title_short | Aspirin Use Is Not Associated with the Risk of Metachronous Gastric Cancer in Patients without Helicobacter pylori Infection |
title_sort | aspirin use is not associated with the risk of metachronous gastric cancer in patients without helicobacter pylori infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745470/ https://www.ncbi.nlm.nih.gov/pubmed/35011936 http://dx.doi.org/10.3390/jcm11010193 |
work_keys_str_mv | AT kimjieun aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT kimtaejun aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT leehyuk aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT leeyeongchan aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT chunghwehoon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT minyangwon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT minbyunghoon aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT leejunhaeng aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection AT kimjaej aspirinuseisnotassociatedwiththeriskofmetachronousgastriccancerinpatientswithouthelicobacterpyloriinfection |